Literature DB >> 7882331

Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells.

B S Zhou1, N Y Hsu, B C Pan, J H Doroshow, Y Yen.   

Abstract

Ribonucleotide reductase (RR) is a rate-limiting enzyme in DNA synthesis. The enzyme consists of two subunits, M1 and M2. Hydroxyurea (HU) is an M2-specific inhibitor. It has been shown that a HU-resistant clone derived from stepwise exposure to HU overexpresses the M2 mRNA and the RR protein (Y. Yen et al., Cancer Res., 54: 3868-3691, 1994). In this study, we established stable clones by transfecting human KB cells with the cDNA of human wild-type RR in which each subunit was overexpressed by a SV40 promoter. The mammalian cell expression vector ph beta APr-1 was used for constructing M1, M2, and M1/M2 subunit cDNA. The transfected cells were selected with G418. The clones designated M2-D, M1-D, X-D, and KB-V represent transfectant clones which contain M2 cDNA, M1 cDNA, M1/M2 cDNA, and vector alone, respectively. The parental KB cells and clones containing vector plasmid KB-V express equally low amounts of M2 and M1 mRNA from the endogenous genes. The expression of M2 mRNA and M1 mRNA is elevated 2-3 fold in the X-D transfectants. M2-D clone demonstrated a 6-fold higher M2 mRNA level although the M1 mRNA expression remains the same as parental cells. M1-D transfectants have a 3-fold increase in M1 mRNA expression relative to parental cells, but reveal no alteration of M2 mRNA. Southern analysis of genomic DNA suggested the incorporation of the plasmid into the genome. The X-D clone revealed both integration of the M2 and M1 gene while the M2-D clone only showed M2 gene integration. The M1-D clone revealed M1 gene integration relative to the parental cells. The Western blot of M2 protein showed a 3-fold increase in the X-D and M2-D clones whereas the M2 protein level in M1-D was the same as it was in parental cells. The M1 protein was increased 3-fold in X-D and 1.5-fold in M1-D over that of parental cells. However, lower M1 protein levels were identified in the M2-D clone. The specific activity of the RR enzyme from each transfectant showed a 3-fold increase in both the X-D and M2-D clones and slightly increased in M1-D clone over that of parental cells. However, X-D and M2-D both demonstrated a 3-fold increase in resistance to HU as compared to M1-D which showed the same sensitivity as the parental enzyme.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882331

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Regulation of the ribonucleotide reductase small subunit gene by DNA-damaging agents in Dictyostelium discoideum.

Authors:  P Gaudet; A Tsang
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

2.  Differential and kinetic effects of cell cycle inhibitors on neoplastic and primary astrocytes.

Authors:  Veetai Li; Thomas J Langan; Kyla R Rodgers; Richard C Chou
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

3.  Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.

Authors:  Charles A Kunos; Steven Waggoner; Vivian von Gruenigen; Elisa Eldermire; John Pink; Afshin Dowlati; Timothy J Kinsella
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

4.  A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.

Authors:  Bingsen Zhou; Leila Su; Shuya Hu; Weidong Hu; M L Richard Yip; Jun Wu; Shikha Gaur; D Lynne Smith; Yate-Ching Yuan; Timothy W Synold; David Horne; Yun Yen
Journal:  Cancer Res       Date:  2013-09-26       Impact factor: 12.701

5.  A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.

Authors:  Steven Attia; Jill Kolesar; Michelle R Mahoney; Henry C Pitot; Daniel Laheru; James Heun; Wei Huang; Jens Eickhoff; Charles Erlichman; Kyle D Holen
Journal:  Invest New Drugs       Date:  2008-02-16       Impact factor: 3.850

6.  Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.

Authors:  Ai-Guo Lu; Hao Feng; Pu-Xiong-Zhi Wang; Ding-Pei Han; Xue-Hua Chen; Min-Hua Zheng
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

7.  Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer.

Authors:  Zhong Zheng; Xueli Li; Michael J Schell; Tingan Chen; David Boulware; Lary Robinson; Eric Sommers; Gerold Bepler
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

8.  Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.

Authors:  Fabrizio Bianchi; Paolo Nuciforo; Manuela Vecchi; Loris Bernard; Laura Tizzoni; Antonio Marchetti; Fiamma Buttitta; Lara Felicioni; Francesco Nicassio; Pier Paolo Di Fiore
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

9.  Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues.

Authors:  Agnes Juhasz; Yun Ge; Susan Markel; Alice Chiu; Linda Matsumoto; Josephus van Balgooy; Krishnendu Roy; James H Doroshow
Journal:  Free Radic Res       Date:  2009-06

10.  Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase.

Authors:  Glen Reid; Natacha Coppieters 't Wallant; Rachna Patel; Ana Antonic; Faamatala Saxon-Aliifaalogo; Helen Cao; Gill Webster; James D Watson
Journal:  J RNAi Gene Silencing       Date:  2009-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.